Policy for Evaluating Impact of Viral Mutations on COVID-19 Tests

On 22 February 2021 the FDA issued initial guidance for test developers and FDA staff.

FDA is issuing this guidance to provide a policy and recommendations on evaluating the potential impact of emerging and future viral mutations of SARS-CoV-2 on COVID-19 tests for the duration of the COVID-19 public health emergency. This guidance describes a policy for test developers to consider the impact of emerging and future variants on their COVID-19 tests during development and post-authorization. Throughout this guidance, references to COVID-19 tests are referring to molecular and antigen tests that detect the SARS-CoV-2 virus and serology tests that detect antibodies to the SARS-CoV-2 virus.

Read more online 
Copyright Widler & Schiemann AG 2020. All Rights Reserved. /